摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-溴-2-环丙氧基苯 | 38380-86-8

中文名称
1-溴-2-环丙氧基苯
中文别名
——
英文名称
1-bromo-2-cyclopropoxybenzene
英文别名
1-bromo-2-cyclopropyloxybenzene
1-溴-2-环丙氧基苯化学式
CAS
38380-86-8
化学式
C9H9BrO
mdl
——
分子量
213.074
InChiKey
MLULTGPYHKKSRT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    253.6±13.0 °C(Predicted)
  • 密度:
    1.533±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    11
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    9.2
  • 氢给体数:
    0
  • 氢受体数:
    1

安全信息

  • 储存条件:
    应存放在室温、密封和干燥的环境中。

SDS

SDS:3ac114226a6208960215e228f5bd3dfd
查看

反应信息

  • 作为反应物:
    描述:
    1-溴-2-环丙氧基苯 在 palladium on activated charcoal 正丁基锂氢气甲基磺酰氯三乙胺 作用下, 以 四氢呋喃二氯甲烷 为溶剂, -78.0~20.0 ℃ 、310.27 kPa 条件下, 反应 21.0h, 生成 4-(2-cyclopropoxy-phenyl)-piperidine-1-carboxylic acid tert-butyl ester
    参考文献:
    名称:
    (Phenylpiperidinyl)cyclohexylsulfonamides: Development of α1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS)
    摘要:
    Although alpha(1), adrenergic receptor blockers can be very effective for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS), their usage is limited by CV-related side-effects that are caused by the subtype non-selective nature of the current drugs. To overcome this problem, it was hypothesized that a alpha(1a/1d) subtype selective antagonist would bring more benefit for the therapy of BPH/LUTS. In developing such selective alpha(1a/1d) ligands, a series of (phenylpiperidinyl)cyclohexylsulfonamides has been synthesized and evaluated for binding to three cloned human alpha(1)-adrenergic receptor subtypes. Many compounds showed equal affinity for both alpha(1a) and alpha(1d) subtypes with good selectivity versus the alpha(1b) subtype. (C) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2007.04.098
  • 作为产物:
    描述:
    溴代环丙烷2-溴苯酚potassium carbonate 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 2.0h, 以17%的产率得到1-溴-2-环丙氧基苯
    参考文献:
    名称:
    INTEGRIN INHIBITORS
    摘要:
    揭示了αvβ6整合素的小分子抑制剂,以及使用它们治疗多种疾病和症状的方法。
    公开号:
    EP3617206A1
点击查看最新优质反应信息

文献信息

  • Substituted &bgr;-alanine derivatives as cell adhesion inhibitors
    申请人:Merck & Co., Inc.
    公开号:US06645939B1
    公开(公告)日:2003-11-11
    &bgr;-Alanine derivatives of Formula I are antagonists of VLA-4 and/or &agr;4&bgr;7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune disorders.
    公式I中的β-丙氨酸衍生物是VLA-4和/或α4β7的拮抗剂,因此在抑制或预防细胞粘附和细胞粘附介导的病理过程中非常有用。这些化合物可以制成药物组合物,并适用于治疗哮喘、过敏、炎症、多发性硬化症和其他炎症性和自身免疫性疾病。
  • MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF
    申请人:Crinetics Pharmaceuticals, Inc.
    公开号:US20190367481A1
    公开(公告)日:2019-12-05
    Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
    本文描述了一种黑色素皮质素亚型-2受体(MC2R)调节剂化合物,制备这种化合物的方法,包含这种化合物的药物组合物和药物,以及使用这种化合物治疗需要调节MC2R活性的疾病、病症或疾患的方法。
  • AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS
    申请人:Castro Palomino Laria Julio Cesar
    公开号:US20110212945A1
    公开(公告)日:2011-09-01
    The present disclosure relates to new azabiphenylaminobenzoic acid derivatives of formula (I); as well as processes for their preparation, pharmaceutical compositions comprising them, and their use in therapy as inhibitors of the dehydroorotate dihydrogenase (DHODH).
    本公开涉及新的式(I)的氮杂联苯氨基苯甲酸衍生物,以及它们的制备方法,包括它们的制药组合物,以及它们在治疗中作为脱氢鸟嘌呤二氢酶(DHODH)抑制剂的用途。
  • Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
    申请人:Crinetics Pharmaceuticals, Inc.
    公开号:US10562884B2
    公开(公告)日:2020-02-18
    Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.
    本文描述了黑色素皮质素亚型-2 受体(MC2R)调节剂化合物、制造此类化合物的方法、包含此类化合物的药物组合物和药物,以及使用此类化合物治疗可从调节 MC2R 活性中获益的病症、疾病或紊乱的方法。
  • Inhibiting (α-V)(β-6) integrin
    申请人:Morphic Therapeutic, Inc.
    公开号:US11021480B2
    公开(公告)日:2021-06-01
    Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of diseases and conditions.
    所公开的是αvβ6整合素的小分子抑制剂,以及用它们治疗多种疾病和病症的方法。
查看更多